Perceptive Advisors LLC recently announced the acquisition of new stake in Agile Therapeutics Inc. (NASDAQ:AGRX). The institutional investor has increased its shareholding in the Healthcare company by 0.00% to 15.92 million shares with purchase of 600.0 shares. This fresh investment now brings its stake to 18.25% valued currently at $39.8 million. In addition, BlackRock Fund Advisors raised its holdings by 3.45 million to 4.7 million shares. And The Vanguard Group, Inc. has lifted its position by 11.42% or 0.38 million shares – to 3.75 million shares.
With over 1.7 million Agile Therapeutics Inc. (AGRX) shares trading Tuesday and a closing price of $3.19 on the day, the dollar volume was approximately $5.43 million. The shares have shown a positive weekly performance of 12.32% and its price on 08/25/20 gained nearly 8.87%. Currently, there are 87.22M common shares owned by the public and among those 67.15M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 4 analysts who have offered their price forecasts for AGRX have a consensus price objective of $8.67. The analysts have set the share’s price value over the next 12 months at a high of $12.00 and a low of $6.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Agile Therapeutics Inc. stock is 1.60 for the next 12 months. But an upside of 73.42% will see the stock hit the forecast high price target while mean target price for the stock is $8.00.
Insiders at the company have transacted a total of 23 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 22 of these insider trades were purchases, accounting for 9,765,235 shares. Insider sales of the common stock occurred on 1 occasions, with total insider shares sold totaling 760,291 shares.
The top 3 mutual fund holders in Agile Therapeutics Inc. are Vanguard Total Stock Market Index, iShares Russell 2000 ETF, and John Hancock Small Cap Core Fund. Vanguard Total Stock Market Index owns 2.85 million shares of the company’s stock, all valued at over $7.12 million. The company bought an additional 0.53 million shares recently to bring their total holdings to about 3.27% of the shares outstanding. iShares Russell 2000 ETF sold 63308.0 shares to see its total holdings shrink to 1.36 million shares valued at over $3.39 million and representing 1.56% of the shares outstanding. John Hancock Small Cap Core Fund bought 1.11 million shares to bring its total holdings to over 1.11 million shares at a value of $2.78 million. John Hancock Small Cap Core Fund now owns shares totaling to 1.27% of the shares outstanding.
Shares of Agile Therapeutics Inc. (NASDAQ: AGRX) opened at $2.94, up $0.01 from a prior closing price of $2.93. However, the script later closed the day at $3.19, up 8.87%. The company’s stock has a 5-day price change of 12.32% and 0.00% over the past three months. AGRX shares are trading 27.60% year to date (YTD), with the 12-month market performance up to 198.13% higher. It has a 12-month low price of $0.35 and touched a high of $4.77 over the same period. Currently, 1.7 million shares have been traded, compared to an average intraday trading volume of 1.70 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 19.04%, 18.91%, and 22.85% respectively.
Institutional ownership of Agile Therapeutics Inc. (NASDAQ: AGRX) shares accounts for 50.80% of the company’s 87.22M shares outstanding. Mutual fund holders own 29.50%, while other institutional holders and individual stakeholders account for 33.10% and 11.51% respectively.
It has a market capitalization of $281.39M and a beta (3y monthly) value of 1.43. The earnings-per-share (ttm) stands at -$0.41. Price movements for the stock have been influenced by the stock’s volatility, which stands at 6.51% over the week and 6.73% over the month.
Analysts forecast that Agile Therapeutics Inc. (AGRX) will achieve an EPS of -$0.18 for the current quarter, -$0.23 for the next quarter and -$0.49 for 2021. The lowest estimate earnings-per-share for the quarter is -$0.18 while analysts give the company a high EPS estimate of -$0.18. Comparatively, EPS for the current quarter was -$0.08 a year ago. Earnings per share for the fiscal year are expected to increase by 34.70%, and 23.40% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 4 brokerage firm advisors rate Agile Therapeutics Inc. (AGRX) as a “Strong Buy” at a consensus score of 1.60. Specifically, 4 Wall Street analysts polled rate the stock as a buy, while 0 of the 4 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the AGRX, a number of firms have released research notes about the stock. Janney stated their Buy rating for the stock in a research note on April 12, 2019, with the firm’s price target at $4. Maxim Group coverage for the Agile Therapeutics Inc. (AGRX) stock in a research note released on November 29, 2018 offered a Buy rating with a price target of $3. William Blair was of a view on December 26, 2017 that the stock is Mkt Perform, while Janney gave the stock Neutral rating on December 26, 2017, issuing a price target of. H.C. Wainwright on their part issued Buy rating on October 02, 2017.